Table 4. Pharmacokinetic parameters of oral losartan in subjects with the CYP2C9*1/*1 and CYP2C9*3/*3 genotypes. Mean±SD.
| Variable | CYP2C9*1/*1 (n=12) | CYP2C9*3/*3 (n=1) |
|---|---|---|
| Losartan | ||
| Cmax (ng/mL) | 235.1±98.4 (172.6, 297.6) | 440.2 |
| t1/2 (h) | 1.92±0.76 (1.44, 2.40) | 4.72 |
| CL/F (L/h) | 0.094±0.018 (0.082, 0.106) | 0.037 |
| AUC0-∞ (ng·h/mL) | 552.2±102.2 (487.3, 617.1) | 1334.9 |
| E-3174 | ||
| Cmax (ng/mL) | 524.3±84.1 (470.8, 577.8) | 19.1 |
| t1/2 (h) | 4.29±0.40 (4.04, 4.54) | 10.56 |
| AUC0-∞ (ng·h/mL) | 3471.9±466.2 (3175.7, 3768.1) | 400.9 |
Values in parentheses represent 95% confidence intervals. Cmax, maximum plasma concentration; AUC0-∞, area under the plasma concentration-time curve from time 0 to infinity; t1/2, elimination half-life; CL/F, apparent oral clearance; n, number of subjects.